Komori
PhoenixBio (6190) · RiskMitigated

Risk of Customer Development Stagnation and Employee Infections Due to COVID-19

First written in FY2020. 6 of 11 entries say "Mitigated", first in FY2022-Q1. Latest entry: FY2024-Q1.

11entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseMaterialisedFY2021-Q1 – FY2021-Q3MitigatedFY2022-Q1 – FY2024-Q12020: 320202021: 320212022: 320222023: 22023
Same theme, other companies
Risk of COVID-19 impacts on business activities, supply chains, demand and financial performanceA theme 1250 companies write about · 1262 as a headwind · 6 as a tailwind

The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 1275 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q1MitigatedAnnual report

    「The classification of COVID-19 under the Infectious Diseases Control Law was changed to Category 5, and the economy is gradually recovering as social and economic activity normalizes.」

    The company states that COVID-19’s legal classification was changed to Category 5 and that social and economic activity is moving toward normalization.
  2. FY2023MitigatedAnnual report

    「Research and development activity at domestic and overseas pharmaceutical companies, the Group’s major customers, has recovered from the stagnation caused by the spread of COVID-19, and demand for PXB mice has increased.」

    The company reports the recovery of customers’ research and development activity from the stagnation caused by COVID-19 and increased demand for PXB mice.
  3. FY2023-Q2MitigatedAnnual report

    「During the cumulative second-quarter period, Japan’s economy was moving toward normalization of social and economic activity as restrictions on movement imposed due to COVID-19 were eased, although」

    The company reports the easing of movement restrictions due to COVID-19 and the normalization of social and economic activity. Demand for customers’ PXB mice also remained firm, particularly in overseas markets.
  4. FY2023-Q1MitigatedAnnual report

    「Although overseas revenue temporarily declined because customers’ research and development activity stagnated due to the impact of COVID-19, it has been recovering since the previous fiscal year, and the order environment remains firm.」

    The company states that overseas revenue is recovering from a temporary decline caused by the stagnation of customers’ research and development activity due to COVID-19, and that the order environment remains firm.
  5. FY2022MitigatedAnnual report

    「Research and development activity at pharmaceutical companies and research institutions, the Group's major customers, recovered from the impact of the COVID-19 pandemic. Development of anti-hepatitis B drugs by overseas pharmaceutical companies was also active, and revenue remained firm in both the domestic and overseas markets.」

    The company reports recovery from the stagnation of customers’ research and development activity due to COVID-19 and firm revenue trends in Japan and overseas. The risks of further infections and employee infections remain.
  6. FY2022-Q1MitigatedAnnual report

    「Research and development activity at pharmaceutical companies and research institutions, the Group’s major customers, showed signs of recovery, and revenue remained firm in both the domestic and overseas markets.」

    The company reports signs of recovery from the stagnation of customers’ research and development activity due to COVID-19, with revenue remaining firm in Japan and overseas.
  7. FY2021Recovery in customer activity alongside carryover of projectsAnnual report

    「Research and development activity at pharmaceutical companies, the Group’s major customers, stagnated due to the impact of COVID-19 and continued to do so for an extended period, particularly in some areas of the United States and Europe where infections spread widely. Laboratory operations gradually resumed as economic activity reopened, and orders recovered toward the second half through progress in developing anti-hepatitis B virus drugs in the pharmacology field and approaches to potential customers using the web.」

    Although the stagnation of research and development activity in the United States and Europe continued for an extended period, laboratory operations and orders recovered after economic activity resumed. However, full-year revenue fell below the previous year because projects were carried over to the following fiscal year.
  8. FY2021-Q3MaterialisedAnnual report

    「In overseas markets, where the group is focusing its efforts, orders from major pharmaceutical companies, its main customers, have been delayed because research and development activity has remained stagnant for an extended period in the United States and some parts of Europe, where COVID-19 had spread particularly widely. As a result, overseas sales fell substantially below the prior-year period. In the domestic market, laboratory operations gradually resumed after the state of emergency was lifted in May 2020. Efforts to identify potential customers through web seminars launched as a new initiative during the COVID-19 pandemic contributed to orders, and domestic sales exceeded the prior-year period.」

    The prolonged stagnation of research and development activity in some areas of the United States and Europe has actually resulted in delays in orders from major pharmaceutical companies and overseas revenue falling below the same period of the previous year. The company also reports the resumption of laboratory operations in Japan and the contribution of web seminars to orders.
  9. FY2021-Q2MaterialisedAnnual report

    「Although laboratory operations in Japan and overseas at the Group's principal customers, pharmaceutical companies and research institutions, gradually resumed as economic activity restarted, research and development activities remained stalled in the United States and some parts of Europe, where COVID-19 infections were spreading. As a result, revenue and orders in both the pharmacology and efficacy evaluation and safety-related fields fell below the prior-year period.」

    Although some laboratory operations in Japan and overseas resumed, research and development activity stagnated in some areas of the United States and Europe, causing revenue and orders received in both areas to fall below the same period of the previous year.
  10. FY2021-Q1MaterialisedAnnual report

    「However, laboratory operations at pharmaceutical companies and research institutions, the Group’s major customers, became restricted as COVID-19 spread, resulting in delays and other issues with testing plans. Although laboratory operations in Japan and overseas gradually resumed from June, a full recovery in the order environment had not been achieved because infections were still increasing in some areas of the United States, and both revenue and orders received fell below the same period of the previous year.」

    The company states that COVID-19 actually restricted customers’ laboratory operations and delayed testing plans, resulting in revenue and orders received falling below the same period of the previous year.
  11. FY2020First statedAnnual report

    「If the spread of COVID-19 causes new drug development at pharmaceutical companies, the Group’s major customers, to stagnate, this may affect the Group’s operating performance. As infection-prevention measures, the Group has restricted business travel and visitors, introduced working from home, and installed acrylic partitions, while requiring employees to undergo health checks and consistently use masks, wash their hands, and disinfect with alcohol.」

    The company has newly disclosed the risk that stagnation in pharmaceutical companies’ new drug development and infections among employees due to COVID-19 could affect operating performance and business activities. It explains that changes to and delays in customers’ testing plans have already occurred.
Moved together

"Introduction of a Restricted Stock Compensation Plan" moved the same way as this thread, in the same document, in 4 of its 11 moves.

433332★123456
  1. ★This thread
  2. 1Introduction of a Restricted Stock Compensation Plan4×
  3. 2Expansion in the DMPK/Tox field3×
  4. 3Dependence on the Anti-Hepatitis Virus Drug Market and Market Convergence3×
  5. 4Emergence of Foreign-Exchange Risk3×
  6. 5Share Dilution Through Stock Acquisition Rights3×
  7. 6Circumstances giving rise to significant doubt regarding the going concern assumption2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for PhoenixBio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Customer Development Stagnation and Employee Infections Due to COVID-19 | PhoenixBio Co.,Ltd. (6190) | Komori